An observational study in Crohn Disease (CD), sponsored by GLSMED Learning Health S.A.. Recruiting at 10 sites in 6 countries. Open to participants aged 16 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-29.
Sponsored by GLSMED Learning Health S.A. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Crohn Disease with a site in Portugal — 16 open to participants now, 23 under way, 15 of them phase 3. Crohn Disease · Portugal.
Among the 53 studies in Crohn Disease with a site in Portugal, this one is one of 2 that started in 2026, is one of 8 observational ones, reaches primary completion later than 17 of the 22 other live ones, and was the 52nd registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →16 of the 53 studies in Crohn Disease with a site in Portugal are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Portugal, United States, Argentina and 27 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in Portugal, United States, Argentina and 25 more countries
Ages 18+
GLSMED Learning Health S.A. · Sites in Portugal
Ages 18–75
Hoffmann-La Roche · Sites in Portugal, United States, Argentina and 24 more countries
Ages 16–80
Hoffmann-La Roche · Sites in Portugal, United States, Argentina and 35 more countries
Ages 16–80
A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 16 Years to 35 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 36 · Phase 4 1
First in 2005; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 184 across 646 observational studies indexed under Crohn Disease.
Median enrollment 500 across the 45 interventional studies, 928 across the 8 observational. Of the 29 that completed or were terminated, 27 (93%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 53 have an industry lead sponsor. The 10 most frequent:
GLSMED Learning Health S.A. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
GLSMED Learning Health S.A. has 3 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Crohn Disease with a site in Portugal that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
Add all 4 to your calendar (.ics) → With an account.
Among the 53 studies in Crohn Disease with a site in Portugal, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The PREDICT-CD study aims to validate a risk score for the development of Crohn's disease, based on serological biomarkers and lifestyle-related factors. Given that having a family member with the disease is the strongest known risk factor, the target population will consist of first-degree relatives (aged 16 to 35) of individuals diagnosed with Crohn's disease.
This study will be conducted within Work Package 3 (WP3) of the INTERCEPT project, a consortium funded by the Innovative Health Initiative (IHI). The research will take place across 28 centres in seven countries: Portugal, Spain, France, Italy, the Netherlands, Sweden, and Poland.
To achieve the study objectives, individuals with Crohn's disease (referred to as patients) will be invited to participate and to engage their eligible first-degree relatives. At the baseline visit, the patient's physician will complete a clinical questionnaire covering disease history, treatments, and previous interventions.
At the same time, first-degree relatives (parents, siblings, or children) will donate a blood sample for serum isolation and, optionally, a whole blood and stool sample. They will also complete a questionnaire regarding their health status, habits, and preferences. Follow-up questionnaires will be administered every six months to monitor the onset of symptoms or behavioural changes.
The first-degree relative without a previous diagnosis of Inflammatory Bowel Disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Development of Crohn's disease during the study period
Diagnosis confirmed according to established diagnostic criteria, specifically endoscopy and histopathology
Time frame: From enrolment until end of study follow-up (up to 3 years)
Proportion of first-degree relatives classified as high risk according to the PREDICT-CD risk prediction algorithm
Proportion of enrolled first-degree relatives whose calculated risk score exceeds the predefined threshold for high-risk classification, based on the PREDICT-CD risk prediction algorithm incorporating serological biomarkers and lifestyle/environmental risk factors.
Time frame: From enrolment until end of study follow-up (up to 3 years)
Clinical and lifestyle characteristics of high-risk individuals who develop inflammatory bowel disease
Characterization of high-risk participants who develop incident inflammatory bowel disease during follow-up, including: time from study enrolment to diagnosis; disease phenotype and disease behaviour at diagnosis; disease severity at diagnosis; early-life risk factors; dietary, nutritional and lifestyle factors; smoking exposure; medical and surgical history.
Time frame: From enrolment until end of study follow-up (up to 3 years)
Incidence of newly diagnosed immune-mediated inflammatory diseases other than Crohn's disease
Number and proportion of participants diagnosed with a new immune-mediated inflammatory disease other than Crohn's disease during study follow-up, based on investigator-confirmed clinical diagnoses.
Time frame: From enrolment until end of study follow-up (up to 3 years)
Participant-reported willingness to receive predictive risk information and participate in preventive interventions
Acceptability will be assessed using a study-specific participant questionnaire. The questionnaire will evaluate willingness to receive information regarding Crohn's disease risk, willingness to undergo additional monitoring, willingness to participate in disease-interception or prevention studies, and concerns and preferences related to predictive testing. Responses will be recorded as categorical and Likert-scale measures and summarized descriptively.
Time frame: From enrolment until end of study follow-up (up to 3 years)
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Dec 2029, 44 months after the start.
Of 232 non-industry observational studies under Crohn Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 101. This study's planned 44 months is close to that.
Counting every sponsor, half of 305 studies reached it within 41 months; a quarter within 29 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GLSMED Learning Health S.A.